Analyst Ratings For Antares Pharma Inc (NASDAQ:ATRS)
Today, HC Wainwright reiterated its Buy rating on Antares Pharma Inc (NASDAQ:ATRS) with a price target of $4.50.
There are 3 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Antares Pharma Inc (NASDAQ:ATRS) is Buy with a consensus target price of $5.4375 per share, a potential 50.62% upside.
Some recent analyst ratings include
- 11/7/2018-Antares Pharma Inc (NASDAQ:ATRS) had its Buy rating reiterated by HC Wainwright with a $4.50 price target
- 8/17/2018-Antares Pharma Inc (NASDAQ:ATRS) had its Buy rating reiterated by Piper Jaffray Companies with a $4.00 price target
- 6/23/2017-Antares Pharma Inc (NASDAQ:ATRS) has coverage initiated with a Buy rating and $5.00 price target
- On 10/2/2018 Jacques Gonella, Director, sold 400,000 with an average share price of $3.79 per share and the total transaction amounting to $1,516,000.00.
- On 8/21/2018 Robert F Apple, CEO, sold 43,000 with an average share price of $3.75 per share and the total transaction amounting to $161,250.00.
- On 8/13/2018 Jacques Gonella, Director, sold 49,507 with an average share price of $3.09 per share and the total transaction amounting to $152,976.63.
- On 8/8/2018 Jacques Gonella, Director, sold 250,493 with an average share price of $3.09 per share and the total transaction amounting to $774,023.37.
- On 6/15/2018 Jacques Gonella, Director, sold 565 with an average share price of $2.95 per share and the total transaction amounting to $1,666.75.
- On 6/12/2018 Jacques Gonella, Director, sold 200,000 with an average share price of $2.73 per share and the total transaction amounting to $546,000.00.
- On 6/5/2018 Jacques Gonella, Director, sold 256,612 with an average share price of $2.62 per share and the total transaction amounting to $672,323.44.
About Antares Pharma Inc (NASDAQ:ATRS)
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Recent Trading Activity for Antares Pharma Inc (NASDAQ:ATRS)
Shares of Antares Pharma Inc closed the previous trading session at 3,61 +0,12 3,44 % with 3.78 shares trading hands.